Status:
UNKNOWN
REMOTE Ischemic Perconditioning Among Acute Ischemic Stroke Patients ( REMOTE-CAT)
Lead Sponsor:
Institut de Recerca Biomèdica de Lleida
Collaborating Sponsors:
Instituto de Salud Carlos III
Conditions:
Ischemic Stroke
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Stroke is one of the leading causes of death worldwide and the main cause of incapacity. Currently, the only therapies for acute ischemic stroke (AIS) patients are the administration of recombinant ti...
Detailed Description
Stroke is one of the leading causes of death worldwide and the main cause of incapacity. Currently, the only therapies for acute ischemic stroke (AIS) patients are the administration of rt-PA and/or e...
Eligibility Criteria
Inclusion
- Age above 18 years old
- Suspected clinical stroke with 8 hours since onset of neurological symptoms
- Stroke code (SC) activation
- Independent in daily life before the onset of acute symptoms. (mrs\</=2)
- Rapid arterial occlusion evaluation (RACE) scale score\>0 and RACE motor item\>0
- Written informed consent (patient or representative)
Exclusion
- Unknown onset of symptoms
- Coma (GCS\< 8)
- Malignancy or significant co-morbidity thought to limit life expectancy to \<6 months
- Pregnancy
- Taking part in another interventional study
Key Trial Info
Start Date :
August 7 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
572 Patients enrolled
Trial Details
Trial ID
NCT03375762
Start Date
August 7 2019
End Date
April 1 2024
Last Update
January 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biomedical Research Institute of Lleida (IRBLleida) Institut de Recerca Biomèdica de Lleida
Lleida, Spain, 25198